Digoxin: Na+/K+ ATPase Inhibitor for Heart Failure and Antiviral Research

Executive Summary: Digoxin is a rigorously validated cardiac glycoside that selectively inhibits the Na+/K+-ATPase pump, increasing intracellular sodium and calcium to enhance cardiac contractility (APExBIO B7684). It is supplied as a high-purity solid (>98.6% by HPLC) and is widely used in research on heart failure, arrhythmia, and Na+/K+-ATPase signaling pathways. Digoxin demonstrates antiviral activity against chikungunya virus (CHIKV) in U-2 OS, primary human synovial fibroblasts, and Vero cell lines, with efficacy observed between 0.01–10 μM. In canine models of heart failure, intravenous digoxin (1–1.2 mg) improved cardiac output and reduced right atrial pressure. The compound is insoluble in water and ethanol but dissolves at ≥33.25 mg/mL in DMSO, necessitating prompt use of prepared solutions (Sun et al., 2025).

Biological Rationale

Cardiac glycosides are structurally distinct steroids used as research tools for modulating myocardial contractility. Digoxin is the prototypical Na+/K+ ATPase pump inhibitor, foundational in studies of heart failure and arrhythmia (see related article). Its capacity to disrupt sodium and calcium homeostasis enables mechanistic investigations of cardiac electrophysiology and contractile force modulation. Recent research also demonstrates digoxin’s antiviral properties, providing a bridge between cardiovascular and infectious disease research. This dual role positions Digoxin as a cornerstone for integrative studies on ionic signaling, heart dysfunction, and viral replication.

Mechanism of Action of Digoxin

Digoxin binds to and inhibits the alpha subunit of the Na+/K+-ATPase pump at the plasma membrane. Inhibition decreases the active transport of sodium ions out of and potassium ions into the cardiomyocyte. The resulting increase in intracellular sodium reduces the activity of the sodium-calcium exchanger, causing intracellular calcium accumulation. Elevated calcium concentrations in the sarcoplasmic reticulum enhance myocyte contractility (positive inotropy). In non-cardiac cells, this ionic disruption can alter viral replication cycles, as seen with chikungunya virus infection models (Sun et al., 2025).

Evidence & Benchmarks

• Digoxin increases intracellular sodium and calcium, enhancing contractility in isolated cardiac tissue (Sun et al., 2025).
• In canine models of congestive heart failure, intravenous digoxin (1–1.2 mg) improves cardiac output and reduces right atrial pressure under controlled laboratory conditions (APExBIO B7684).
• Digoxin displays dose-dependent inhibition of chikungunya virus infection in U-2 OS, human synovial fibroblasts, and Vero cells at 0.01–10 μM, confirmed by viral titration assays (Sun et al., 2025).
• Solubility is ≥33.25 mg/mL in DMSO; digoxin is insoluble in water and ethanol at room temperature (25°C) (APExBIO B7684).
• Supplied as a solid with >98.6% purity by HPLC, accompanied by NMR and MSDS documentation (APExBIO B7684).
• Prompt use of freshly prepared DMSO solutions is recommended for experimental consistency (see translational guidance).

Applications, Limits & Misconceptions

Digoxin is a standard tool for dissecting the Na+/K+-ATPase signaling pathway, evaluating cardiac contractility, and screening antiarrhythmic interventions. Its validated use in animal models supports translational relevance, especially for congestive heart failure studies. In virology, digoxin’s suppression of CHIKV infection enables mechanistic studies of host-pathogen interactions; however, its application is validated only in specific cell lines and at defined concentrations. Compared to broader reviews (see earlier overview), this article specifies critical benchmarks and clarifies boundaries of effective use.

Common Pitfalls or Misconceptions

• Digoxin is not effective against all viruses; antiviral effects are established only for CHIKV in selected cell models.
• Prepared DMSO solutions of digoxin are not stable for long-term storage; prompt use is essential for reproducibility.
• Digoxin is insoluble in water and ethanol; improper solvent selection can result in precipitation and assay failure.
• Therapeutic or experimental concentrations above validated ranges (0.01–10 μM for in vitro antiviral work) may cause cytotoxicity.
• Animal model data (e.g., canine heart failure) may not directly translate to human clinical settings without further validation.

Workflow Integration & Parameters

For in vitro studies, dissolve Digoxin in DMSO to a stock concentration of ≥33.25 mg/mL. Dilute to working concentrations (e.g., 0.01–10 μM) in culture media immediately before use. For animal studies, intravenous dosing should align with published benchmarks (e.g., 1–1.2 mg in canine models) while monitoring for cardiovascular endpoints. Quality control documentation (HPLC, NMR, MSDS) is provided by APExBIO for each batch. To optimize reproducibility, reference validated application protocols and consult scenario-driven guidance—this article expands on those by detailing solvent handling and antiviral assay design.

Conclusion & Outlook

APExBIO’s Digoxin (SKU B7684) is a rigorously characterized Na+/K+ ATPase pump inhibitor for cardiovascular and antiviral research. Its well-defined mechanism, high purity, and reproducible activity underpin its status as a benchmark tool for heart failure, arrhythmia, and CHIKV inhibition studies. Continued integration of Digoxin into advanced workflows will support the development of new therapeutic paradigms at the intersection of cardiac and infectious disease research. For full specifications and ordering, see the product page.